ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant Therapy
- Conditions
- Breast Neoplasms
- Interventions
- Procedure: ICG+Methylene Blue
- Registration Number
- NCT02869815
- Lead Sponsor
- Peking University People's Hospital
- Brief Summary
The value of sentinel lymph node biopsy (SLNB) in patients underwent neoadjuvant chemotherapy is controversial. Lower detection rate and higher false negative rate are the main problem. The purpose of this study is to determine the detection rate and the false negative rate of SLNB by indocyanine green (ICG) in addition to blue dye (methylene blue) after neoadjuvant chemotherapy in patients with large or locally advanced breast cancer. This is a single arm clinical trial.
- Detailed Description
Patients indicated for neoadjuvant therapy would be recruited in this study. During the surgery, SLNB using the dual tracing method would be applied before axillary clearance. After the surgery, histological results of the SLN and non-SLN would be analysed.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 150
- Patients indicated for neoadjuvant therapy
- Have complete evaluation of the axillary status
- Planned for axillary clearance after neoadjuvant therapy
- Sensitive to Iodine
- Inflammatory disease
- Patient's refusal to join the trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ICG+Methylene Blue ICG+Methylene Blue ICG+Methylene Blue: Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery.
- Primary Outcome Measures
Name Time Method Detection rate of SLN Immediate The number of successful SLNB / total number of SLNB
- Secondary Outcome Measures
Name Time Method False negative rate of SLNB 1 week after the surgery The number of patients with positive SLN / the number of patients with positive node
Adverse effect Half a year after the surgery Prophylaxis reaction, skin complication
Trial Locations
- Locations (1)
Breast Center, Peking University People's Hospital
🇨🇳Beijing, Beijing, China